Our new leadership team continues to author a new future for Pineapple Energy, with a focus on elevating our corporate governance, properly aligning our cost structure, creating a new corporate ...

Lumos Pharma, Inc. faces a significant risk concerning the potential valueless expiration of the Contingent Value Rights (CVRs) offered to stockholders post-2024 Merger and Offer completion.

Pineapple Energy (PEGY) will distribute to the holders of its non-transferable Contingent Value Rights a payment of $850,269, or $0.35 per CVR.

Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...

Lumos expects to begin the trial in the second quarter of next year. The contingent value rights would trigger payment if certain revenue goals for LUM-201 up to the year 2037 were reached ...

Total revenue for the fiscal third quarter of 2024 was $95.4 million, and consisted of $68.1 million in Digital asset ...